

# A plea for systematic literature analysis and conclusive study design

*Comment on: “Systematic review of magnetic resonance imaging for diagnosis of Meniere disease”*

Robert Gürkov\*

*Department of Otorhinolaryngology Head and Neck Surgery, Klinikum Bielefeld, Bielefeld, Germany*

Robert Gürkov\*      guerkov@arcor.de  
Krisztina Barath      krisztina.barath@rnrglatt.ch  
Bert de Foer      Bert.DeFoer@GZA.BE  
Munehisa Fukushima      mfukushima@kansaih.johas.go.jp  
Michael Gluth      mgluth1@surgery.bsd.uchicago.edu  
Jeremy Hornibrook      jeremy@jhornibrook.com  
Nicolas Perez-Fernandez      nperezfer@unav.es  
Ilmari Pyykkö      Ilmari.Pyykko@uta.fi  
Michihiko Sone      michsone@med.nagoya-u.ac.jp  
Shin-Ichi Usami      michsone@med.nagoya-u.ac.jp  
Wuqing Wang      wwuqing@eent.shmu.edu.cn  
Jing Zou      Zou<Jing.Zou@staff.uta.fi  
Shinji Naganawa      naganawa@med.nagoya-u.ac.jp

Lopez-Escamez and Attyé present a review article on the topic of endolymphatic hydrops (ELH) imaging [40]. Within the last decade, ELH imag-

---

\*Corresponding author: Robert Gürkov, Department of Otorhinolaryngology Head and Neck Surgery, Klinikum Bielefeld, Teutoburger Str. 50, 33604 Bielefeld, Germany. E-mail: guerkov@arcor.de.

ing has greatly impacted the field of otology and has prompted an ongoing shift in the diagnostic paradigm for Menière’s disease (MD) from a purely clinical-based diagnosis to one that also takes into account objective visualization of the chief histopathologic correlate known to occur in this condition—namely endolymphatic hydrops (MD)~ [20, 21]. Because the traditional symptom-based systems used to diagnose MD have long been known to lack ideal specificity and sensitivity, it is therefore of great clinical interest to systematically analyze the published literature on this topic since 2007, and in this regard, we praise the authors’ intent.

Nevertheless, several aspects of this review are concerning, and we believe the main presented conclusions are overly simplified and not entirely supported by a full consideration of the relevant literature. Some of these issues likely stem from the methodology applied in this effort, but also the review does not really systematically seek to study a specifically pre-defined primary outcome measure. Rather, it presents a limited listing of articles and then provides generalized commentary on several issues related to imaging of MD. In the following, we present a few key concerns in order to offer an alternative broader view onto this topic.

One major area of concern relates to the unclear and seemingly inconsistent basis for study inclusion. First, the authors excluded studies without control groups or studies that used the contralateral ear as a

Table 1  
Case control studies on endolymphatic hydrops imaging which have been excluded by a recent review article [40]

1 <sup>st</sup> author	year	ref.	clinical diagnostic criteria	contrast	imaging	Definite MD cases / controls	prevalence of ELH in cases
Fiorino	2011	[5]	AAOHNS 1995	i.t. Gd	3D FLAIR	Definite MD ( $n = 26$ ) / Non-MD inner ear disorders ( $n = 11$ )	100%
Fukushima	2017	[8]	AAOHNS 1995	i.v. Gd	3D FLAIR	Definite MD ( $n = 11$ ) / healthy control subjects ( $n = 3$ )	measured ELH volume ratio
Grieve	2012	[9]	AAOHNS 1995	i.t. Gd	PS-IR	Definite MD ( $n = 12$ ) / healthy control subjects ( $n = 2$ )	100%
Hagiwara	2014	[25]	AAOHNS 1995	i.v. Gd	3D FLAIR	Definite MD ( $n = 10$ ) / healthy control subjects ( $n = 5$ )	Sensitivity / Specificity = 85% / 89%
Homann	2015	[28]	AAOHNS 1995	i.v. Gd	3D FLAIR	Definite MD ( $n = 10$ ) / healthy control subjects ( $n = 2$ )	n.a. (at least 73%)
Hornibrook	2015	[29]	AAOHNS 1995	i.t. Gd	3D FLAIR	Definite MD ( $n = 30$ ) / asymmetric hearing loss or tinnitus ( $n = 45$ )	47% (vs < 8% in controls)
Katayama	2010	[36]	AAOHNS 1995	i.t. Gd	3D FLAIR, 3D Real-IR	Definite MD ( $n = 19$ ) / SSNHL ( $n = 4$ )	100%
Liu	2012	[39]	AAOHNS 1995	i.t. Gd	3D FLAIR	Definite MD ( $n = 6$ ) / healthy control subjects ( $n = 20$ )	100%
Sun	2017	[49]	Barany S. 2015	i.t. Gd	3D Real-IR	Definite MD ( $n = 30$ ) / definite or probable VM ( $n = 30$ )	100% (vs. 5% in controls)

control; yet, details of what constituted an acceptable control group are not provided. Second, the authors excluded studies from the years 2007–2012, without offering a clear justification for this temporal selectivity. This is concerning as clinical ELH imaging is being performed since 2007. Third, the inclusion criteria do not require defined clinical diagnostic criteria of MD for patient selection. In fact, their presented list of included studies lists 3 studies (i.e. 23% of all included studies) that did not report any MD diagnostic criteria. Forth, eight controlled studies, four from the years 2010–2012 [5, 9, 36, 39] and another four from the years 2014–2017 [8, 25, 28, 29], were not included, for reasons that are not entirely clear (Table 1). All of these studies included healthy controls and seemingly should have been included. Lastly, there is no flow diagram to outline search results, inclusion, and exclusion as is generally recommended in a systematic review according to PRISMA guidelines.

It appears difficult to pursue the authors' main stated objective of this review (to determine if visualization of ELH on MRI can be used as diagnostic criteria for MD) while excluding a large number of controlled studies which appear to fulfill the presented inclusion criteria. Furthermore, the authors state that in order to pursue this main objective they retrieved certain data from the selected studies such as duration of disease (reported in only 2 of the selected studies) and technical MR parameters. However, they

did not retrieve data fundamental to their stated aim such as the proportion of patients correctly diagnosed by MR imaging as compared to a narrowly defined clinical standard (such as define MD) or by other electrophysiologic diagnostic methods. These data would have been necessary to examine the main hypothesis of this review (can visualization of EH on MRI be used as diagnostic criteria for MD?).

In the authors' inclusion criteria, they allowed inclusion of patients with vestibular migraine, but only according to the diagnostic criteria published in 2012 by Lempert et al. [37], and not the diagnostic criteria published by Neuhauser and Lempert in 2009 [45]. This decision seems somewhat arbitrary when considering the accepted criteria for MD originate from 1995, and also considering that the difference between the 2009 and the 2012 criteria for VM is subtle. This selection strategy, for example, led to the exclusion of the publication from the year 2013 [23], which demonstrated for the first time in the published literature the presence of endolymphatic hydrops in patients with the symptom-based diagnosis of vestibular migraine (according to the 2009 criteria by Neuhauser et al.). This discovery is of extraordinary importance for the understanding of MD and VM and the clinical picture of patients with ELH.

Furthermore, concerning the diagnostic criteria, the authors make no distinction between the clinically disparate patient groups of "definite", "probable" and

“possible” MD. This is a major problem because opening analysis to probable and possible cases would bias conclusions drawn concerning the main hypothesis of this review unless their intent had been to correlate these sub groups of MD with imaging outcomes, but that was not the case.

Under the heading “Knowledge from controlled studies”, the authors – rather than presenting the usual sort of data such as sensitivity/specificity – merely provide commentary on aspects of ELH imaging that have little to do with data gleaned from systematically reviewing the articles included.

For example, the different MR hydrops grading systems have been developed and published in non-controlled studies. The authors mention only two grading methods (the 3-stage grading by Naganawa et al. and their own 2-stage grading), but they do not mention, for example, the grading proposed by Barath et al. [1] or the 4-stage grading proposed by Bernaerts et al. [2] or the 4-stage grading [19] and volumetric grading by Gürkov et al. [13]. The latter of these 4-stage grading scales has been used for generating novel insights into the structure-function-correlations between ELH severity and audiovestibular functions [18, 19, 31] and for a longitudinal follow-up study of the effect of placebo treatment on ELH severity [16]. The volumetric grading method has established a semi-automated quantification method for cochleovestibular ELH and has been used to confirm the strong positive correlation between hearing loss and ELH severity in MD patients [13].

Once again, the stated aim of the review article was to investigate if visualization of EH on MRI can be used as diagnostic criteria for MD, but it is hard to see how that question could possibly have been answered by the data that the authors actually present. The main table (Table 2) merely lists some studies with a control group, but actually present no data that is particularly useful to accomplish the main purpose. In fact, the only instance in the entire paper where the authors present data about sensitivity and specificity is a citation from one single study [47] that *did not even use any contrast agent* for the visualization of ELH. This method is possibly based on artefacts [4] and furthermore questionable, since endolymph and perilymph currently cannot be reliably distinguished without any contrast enhancement. Moreover, four of the 13 included studies did not use any contrast agent, and a further two studies [6, 26] were not even concerned with ELH imaging at all.

Under the heading “differential diagnoses for MD”, the authors selectively mention one single

study from their own group. Interestingly, this study found ELH in only 48% of patients with clinically definite MD, whereas a large number of studies from other groups found rates of 100% or close to 100% of ELH in patients with clinically definite MD [1, 3, 5, 18, 19, 30, 36, 39, 46, 49, 50, 52]. In other words, the authors’ own paper that is discussed is in fact an outlier within the scope of the relevant medical literature, but this discrepancy is not discussed.

The authors further state that their own referenced study showed that patients with MD-like symptoms can also have inner ear lesions such as malformations. This is not a new finding, as it has been reported previously [27, 44]. Furthermore, several other previous publications (e.g. [7, 22, 33, 34, 51] from other groups have documented ELH in patients with various inner ear lesions—a phenomenon equally well documented in histopathological temporal bone studies.

Perhaps one of the most significant concepts that has emerged from imaging of ELH is the realization that “clinical” MD likely only represents a subset of patients with ELH and clinical symptoms—who often do not fit the “typical” clinical definition of MD (reviewed in [24]), as for example vertigo may be absent. In other words, the old symptom-based concept of MD is simply too narrow to fully account for the complete range of symptomatic ELH. This has led to the development of the clinical-practical concept of Hydropic Ear Disease, which defines a larger spectrum of ELH that includes clinical variants as well as the primary and secondary forms of MD within one single classification [10, 11, 20, 21].

The authors state that they have not found any longitudinal follow-up studies. However, a cursory Medline search will reveal several longitudinal follow-up studies, both with and without control groups [8, 15, 32, 38].

Under the heading “conclusions on MRI findings in MD”, the authors state three main conclusions. The first conclusion claims that ELH could be reliably measured in the saccule using the SURI method. However, such a conclusion is not supported by the presented data. In order to examine this hypothesis, an entirely different study design of the review article would have been necessary (that would have included relevant saccular imaging data points). Also, to this purpose, it is irrelevant whether an MRI study has a control group or not, because the ability to measure an anatomic structure does not depend on the patient’s symptoms, but on many other (mostly technical) factors. These factors include the (in)ability

to differentiate two adjacent structures, e.g. utriculus and sacculus with the same signal intensity and without a visible border between them. Besides this questionable SURI method, the sacculus utriculus confluence criterion has been proposed by Bernaerts et al. [2]. Related, the conclusion presented by the authors in the abstract “studies have identified the saccule as the most specifically involved structure in MD” similarly has no justification based on the work done in this study and is seemingly just a recapitulation of the authors’ previously published opinions.

The second main conclusion of the review article relates to the association between endolymphatic hydrops and hearing loss. While this point has previously been discovered in 2011 [19] and has been confirmed several times in the previous literature (e.g. [8, 13, 28]), the larger point remains that this review does not systematically present hearing data. To examine such a hypothesis with a systematic review another study design that would include hearing status data review would have been advisable.

The third and final conclusion of the review article states that uncontrolled studies have described ELH in patients with vestibular migraine, acute low tone SNHL (without vertigo) and in other clinical pictures. However, there are no references given to these studies (e.g. [23]).

The authors state that they “have selected case-controlled studies to better characterize the potential added value in the diagnosis”. This is a problematic concept. If one accepts MRI diagnosis as a “new test” and the symptom-based diagnosis as the “gold-standard” as seems to be implied by the authors’ assertion that MD is a clinical diagnosis, then it is impossible to characterize the “added diagnostic value” of the MRI. With such an approach, the MRI diagnosis can never be as good as or better than the simple clinical diagnosis. There would be no clinical sense in performing an expensive MRI if the best possible diagnostic result would be a confirmation of a diagnosis which is already established by a ten-minute interview and a simple audiogram. Yet, the troublesome limitations of clinical-based diagnosis are in fact the driving force that has motivated researchers to apply MRI in the diagnostic approach for patients suspected of having MD or other forms of Hydropic Ear Disease. The rationale behind MR imaging of ELH is in fact based on a desire to seek improved diagnostic precision based on the proven histopathological correlation between ELH and MD. It is an attempt to visualize clinically what is known

to be present post mortem in order to work toward an improved diagnostic “gold-standard.”

In our experience, the real added clinical value of the hydrops MRI is the identification of patients who would be missed by the simple history-based clinical diagnostic criteria [21]. Therefore, to assess the potential added value of MRI, it would be advisable to examine patients with undiagnosed audiovestibular symptoms who would not be diagnosed with definite MD by using the simple clinical criteria.

The authors state that “Meniere disease (MD) is a clinical syndrome”. This opinion, however, should not be considered in isolation. Instead, alternative expert opinions should equally be considered and cited, e.g. the AAO-HNS classifications of 1972, 1985 AND 1995 as well as the new classification of Hydropic Ear Disease [20], all of which are in clear contradiction to this opinion. The authors’ opinion to regard MD as a mere “syndrome” does not appear to have a conclusive scientific basis. The pathognomonic pathological sign is well-recognized to be endolymphatic hydrops. Therefore the terms of “syndrome” and “disease” should not be confused, as it is the case in the recently proposed clinical diagnostic criteria [20]. We are considering MD as a disease and therefore the disease concept includes not only certain symptoms but also the underlying pathology, i.e. ELH.

The authors state that “clinicians should interpret these images with caution to exclude description of endolymph in non-physiologic compartment due to geometric coregistration problems between the two sequences [18].” However, here the authors cite their own letter to the editor. In this letter, the authors make false statements about an article by another group [10] and wrongly claim that another article by this group [32] had used a coregistration method, which is a false speculation and has already been publicly disproven [12]. It seems hard to understand why the authors are now making the same wrong and disproven insinuation again in the format of a review article.

The authors state that intratympanic contrast injection “can cause local toxicity in animal models [33].” However, their review article is concerned with a clinical question (can visualization of EH on MRI be used as diagnostic criteria for MD?), and therefore it seems hard to understand why the authors only cite one single animal study in which a non-clinical Gd dilution was used. In contrast, the authors do not cite any of the clinical studies (e.g. [41–43]) that have examined the potential ototoxic effects of clinically

used intratympanic Gd applications in humans. Furthermore, the clinically used Gd dilution was also found to be safe (endocochlear potential, electron microscopy) in an animal study [35].

The authors state that “A recent meta-analysis of temporal bone studies also proposed a cochleocentric distribution of the endolymph fluid with constant cochlear duct dilatation in healthy subjects [41], explaining the frequent visualization of endolymph in normal cochlear ducts with MRI.” However, this narrative is misleading. The first of the two original studies referenced therein is from Minnesota [48], from the year 1993. It included 13 bones from 11 patients. These 11 patients were *chosen* from the temporal bone collection *based* on the presence of ELH and the absence of typical MD symptoms (i.e. fluctuating hearing loss and vertigo attacks). Of these 11 patients, 8 had otopathology such as chronic otitis media, otosclerosis, serous labyrinthitis, acute otitis media with effusion, and metastatic carcinoma. In 11 of the 13 bones, the ELH was *only* apical. The second original study [53] was from Massachusetts, from the year 1982. It examined 495 bones from 300 patients. The majority of these patients had otopathologic diagnoses of chronic otitis media and otosclerosis. They found *apical* ELH in 78 bones from 66 subjects. The incidence of apical ELH for the entire population studied was 15.8%. Therefore, to consider the patients of these temporal bone studies as “healthy subjects” is misleading as they in fact had various forms of ear disease.

Furthermore, with their statement “constant cochlear duct dilation in healthy subjects” they convey the impression that ELH was something non-pathologic. However, an abnormal distension of the endolymph space, i.e. endolymphatic hydrops, is clearly established as a significant inner ear pathology, and a recent *in-vivo* study revealed that Hydropic Ear Disease is associated with a broad array of audiovestibular symptoms [21], and not only the simplified typical symptoms used in the clinical diagnostic criteria.

The authors state that “The absence of inclusion of grading for utricular protrusion into the lateral semicircular canal following IT contrast media injection [45] could limit this classification’s [SURI grading] usefulness.” However, this citation appears misleading, since it is referring to a letter void of original research data. The MRI discovery of hydropic herniation from the vestibulum into the semicircular canal has originally been described by Gürkov et al. in 2012 [14, 17].

In summary, this article is an apparently inconsistent execution of a systematic review that seemingly displays deficient and contradictory inclusion criteria that are also inconsistently applied. A large number of relevant studies are unfortunately omitted for reasons unknown. The data presented are not framed in a manner that allow evidence to suggest an answer to a clearly-stated hypothesis. The conclusions that are presented cannot be drawn from the actual data gleaned by systematically reviewing the literature, nor is the underlying design suitable to support most of these conclusions. The result of these deficiencies is an article that will likely confuse most readers and possibly be interpreted in a way that would partially discredit MRI as a viable emerging tool in the diagnosis of the spectrum of ear diseases. We propose that systematic reviews on ELH imaging be conducted in a transparent and conclusive manner in the future.

## References

- [1] K. Barath, B. Schuknecht, A.M. Naldi, T. Schrepfer, C.J. Bockisch and S.C. Hegemann, Detection and grading of endolymphatic hydrops in Meniere disease using MR imaging, *AJNR Am J Neuroradiol* **35** (2014), 1387–1392.
- [2] A. Bernaerts and B. De Foer, Imaging of Meniere Disease, *Neuroimaging Clin N Am* **29** (2019), 19–28.
- [3] G. Bier, M.N. Bongers, C. Schabel, W. Heindel, U. Ernemann and J.M. Hempel, *In vivo* Assessment of an Endolymphatic Hydrops Gradient Along the Cochlea in Patients With Meniere’s Disease by Magnetic Resonance Imaging-A Pilot Study, *Otology & Neurotology* **39** (2018), e1091–e1099.
- [4] P. Dominguez and S. Naganawa, Letter to the editor on the article “Saccular measurements in routine MRI can predict hydrops in Meniere’s disease” by Simon F. et al., *Eur Arch Otorhinolaryngol* **275** (2018), 311–312.
- [5] F. Fiorino, F.B. Pizzini, A. Beltramello, B. Mattellini and F. Barbieri, Reliability of magnetic resonance imaging performed after intratympanic administration of gadolinium in the identification of endolymphatic hydrops in patients with Meniere’s disease, *Otology & Neurotology* **32** (2011), 472–477.
- [6] W.H. Flatz, A. Henneberger, M.F. Reiser, R. Gurkov and B. Ertl-Wagner, *In Vivo* Morphometric Analysis of Human Cranial Nerves Using Magnetic Resonance Imaging in Meniere’s Disease Ears and Normal Hearing Ears, *J Vis Exp* (2018).
- [7] H. Fukuoka, K. Tsukada, M. Miyagawa, T. Oguchi, Y. Takumi, M. Sugiura, H. Ueda, M. Kadoya and S.-i. Usami, Semi-quantitative evaluation of endolymphatic hydrops by bilateral intratympanic gadolinium-based contrast agent (GBCA) administration with MRI for Meniere’s disease, *Acta Oto-laryngologica* **130** (2010), 10–16.
- [8] M. Fukushima, T. Kitahara, R. Oya, S. Akahani, H. Inohara, S. Naganawa and N. Takeda, Longitudinal up-regulation of endolymphatic hydrops in patients with Meniere’s disease

- during medical treatment, *Laryngoscope Investig Otolaryngol* **2** (2017), 344–350.
- [9] S.M. Grieve, R. Obholzer, N. Malitz, W.P. Gibson and G.D. Parker, Imaging of endolymphatic hydrops in Meniere's disease at 1.5 T using phase-sensitive inversion recovery: (1) demonstration of feasibility and (2) overcoming the limitations of variable gadolinium absorption, *Eur J Radiol* **81** (2012), 331–338.
- [10] R. Gurkov, Meniere and Friends: Imaging and Classification of Hydropic Ear Disease, *Otology & Neurotology* **38** (2017), e539–e544.
- [11] R. Gurkov, [On the diagnosis of Meniere's disease : Discussion of the new criteria], *HNO* **65** (2017), 877–882.
- [12] R. Gurkov, A Warning About The Drawing of Wrong Conclusions From a Failure to Reproduce Other Researchers' Findings, *Otology & Neurotology* **39** (2018), 655–658.
- [13] R. Gurkov, A. Berman, O. Dietrich, W. Flatz, C. Jerin, E. Krause, D. Keeser and B. Ertl-Wagner, MR volumetric assessment of endolymphatic hydrops, *Eur Radiol* **25** (2015), 585–595.
- [14] R. Gurkov, W. Flatz, B. Ertl-Wagner and E. Krause, Endolymphatic hydrops in the horizontal semicircular canal: A morphologic correlate for canal paresis in Meniere's disease, *Laryngoscope* **123** (2013), 503–506.
- [15] R. Gurkov, W. Flatz, D. Keeser, M. Strupp, B. Ertl-Wagner and E. Krause, Effect of standard-dose Betahistine on endolymphatic hydrops: An MRI pilot study, *Eur Arch Otorhinolaryngol* (2012).
- [16] R. Gurkov, W. Flatz, D. Keeser, M. Strupp, B. Ertl-Wagner and E. Krause, Effect of standard-dose Betahistine on endolymphatic hydrops: An MRI pilot study, *Eur Arch Otorhinolaryngol* **270** (2013), 1231–1235.
- [17] R. Gurkov, W. Flatz, J. Louza, M. Strupp, B. Ertl-Wagner and E. Krause, Herniation of the membranous labyrinth into the horizontal semicircular canal is correlated with impaired caloric response in Meniere's disease, *Otology & Neurotology* **33** (2012), 1375–1379.
- [18] R. Gurkov, W. Flatz, J. Louza, M. Strupp, B. Ertl-Wagner and E. Krause, *In vivo* visualized endolymphatic hydrops and inner ear functions in patients with electrocochleographically confirmed Meniere's disease, *Otology & Neurotology* **33** (2012), 1040–1045.
- [19] R. Gurkov, W. Flatz, J. Louza, M. Strupp and E. Krause, *In vivo* visualization of endolymphatic hydrops in patients with Meniere's disease: Correlation with audiovestibular function, *Eur Arch Otorhinolaryngol* **268** (2011), 1743–1748.
- [20] R. Gurkov and J. Hornibrook, On the classification of hydropic ear disease (Meniere's disease), *HNO* (2018).
- [21] R. Gürkov, C. Jerin, W. Flatz and R. Maxwell, Clinical Manifestations of Hydropic Ear Disease (Menière), *Eur Arch Otorhinolaryngol* (2018).
- [22] R. Gürkov, R. Kalla, R. Maxwell and M. Patzig, Hydropic Ear Disease - Translation of imaging into clinical practice, *Clinical and Translational Neuroscience* **2** (2018).
- [23] R. Gurkov, C. Kantner, M. Strupp, W. Flatz, E. Krause and B. Ertl-Wagner, Endolymphatic hydrops in patients with vestibular migraine and auditory symptoms, *Eur Arch Otorhinolaryngol* (2013).
- [24] R. Gurkov, I. Pyyko, J. Zou and E. Kentala, What is Meniere's disease? A contemporary re-evaluation of endolymphatic hydrops, *J Neurol* **263**(Suppl 1) (2016), S71–81.
- [25] M. Hagiwara, J.T. Roland, Jr., X. Wu, A. Nusbaum, J.S. Babb, P.C. Roehm, P. Hammerschlag, A.K. Lalwani and G. Fatterpekar, Identification of endolymphatic hydrops in Meniere's disease utilizing delayed postcontrast 3D FLAIR and fused 3D FLAIR and CISS color maps, *Otology & Neurotology* **35** (2014), e337–342.
- [26] A. Henneberger, B. Ertl-Wagner, M. Reiser, R. Gurkov and W. Flatz, Morphometric evaluation of facial and vestibulocochlear nerves using magnetic resonance imaging: Comparison of Meniere's disease ears with normal hearing ears, *Eur Arch Otorhinolaryngol* **274** (2017), 3029–3039.
- [27] K. Higashi-Shingai, T. Imai, Y. Takimoto, T. Okumura, Y. Ohta, T. Morihana, A. Uno, Y. Watanabe, A. Horii and H. Inohara, Gadolinium contrast-enhanced MRI reveals cystic lateral semicircular canal contents, *Acta Otolaryngol* **135** (2015), 1000–1006.
- [28] G. Homann, V. Vieth, D. Weiss, K. Nikolaou, W. Heindel, M. Notohamiprodjo and Y. Bockenfeld, Semi-quantitative vs. volumetric determination of endolymphatic space in Meniere's disease using endolymphatic hydrops 3T-HR-MRI after intravenous gadolinium injection, *PLoS One* **10** (2015), e0120357.
- [29] J. Hornibrook, E. Flook, S. Greig, M. Babbage, T. Goh, M. Coates, R. Care and P. Bird, MRI Inner Ear Imaging and Tone Burst Electrocochleography in the Diagnosis of Meniere's Disease, *Otology & Neurotology* **36** (2015), 1109–1114.
- [30] T. Imai, A. Uno, T. Kitahara, T. Okumura, A. Horii, Y. Ohta, T. Sato, S. Okazaki, T. Kamakura, Y. Ozono, Y. Watanabe, Y. Hanada, R. Imai, K. Ohata and H. Inohara, Evaluation of endolymphatic hydrops using 3-T MRI after intravenous gadolinium injection, *Eur Arch Otorhinolaryngol* **274** (2017), 4103–4111.
- [31] C. Jerin, S. Floerke, R. Maxwell and R. Gurkov, Relationship Between the Extent of Endolymphatic Hydrops and the Severity and Fluctuation of Audiovestibular Symptoms in Patients With Meniere's Disease and MRI Evidence of Hydrops, *Otology & Neurotology* **39** (2018), e123–e130.
- [32] C. Jerin, E. Krause, B. Ertl-Wagner and R. Gurkov, Longitudinal assessment of endolymphatic hydrops with contrast-enhanced magnetic resonance imaging of the labyrinth, *Otology & Neurotology* **35** (2014), 880–883.
- [33] C. Jerin, E. Krause, B. Ertl-Wagner and R. Gurkov, Endolymphatic hydrops in a patient with a small vestibular schwannoma suggests a peripheral origin of vertigo, *Austin J Radiol* **2015** (2015), 1033.
- [34] C. Jerin, E. Krause, B. Ertl-Wagner and R. Gurkov, Clinical features of delayed endolymphatic hydrops and intralabyrinthine schwannoma : An imaging-confirmed comparative case series. English version, *HNO* **65** (2017), 41–45.
- [35] A. Kakigi, M. Nishimura, T. Takeda, T. Okada, Y. Murata and Y. Ogawa, Effects of gadolinium injected into the middle ear on the stria vascularis, *Acta Oto-laryngologica* **128** (2008), 841–845.
- [36] N. Katayama, M. Yamamoto, M. Teranishi, S. Naganawa, S. Nakata, M. Sone and T. Nakashima, Relationship between endolymphatic hydrops and vestibular-evoked myogenic potential, *Acta Oto-laryngologica* **130** (2010), 917–923.
- [37] T. Lempert, J. Olesen, J. Furman, J. Waterston, B. Seemungal, J. Carey, A. Bisdorff, M. Versino, S. Evers and D. Newman-Toker, Vestibular migraine: Diagnostic criteria, *J Vestib Res* **22** (2012), 167–172.
- [38] F. Liu, W. Huang, Q. Chen, X. Meng, Z. Wang and Y. He, Noninvasive evaluation of the effect of endolymphatic sac decompression in Meniere's disease using magnetic resonance imaging, *Acta Otolaryngol* **134** (2014), 666–671.

- [39] F. Liu, W. Huang, X. Meng, Z. Wang, X. Liu and Q. Chen, Comparison of noninvasive evaluation of endolymphatic hydrops in Meniere's disease and endolymphatic space in healthy volunteers using magnetic resonance imaging, *Acta Otolaryngol* **132** (2012), 234–240.
- [40] J.A. Lopez-Escamez and A. Attye, Systematic review of magnetic resonance imaging for diagnosis of Meniere disease, *Journal of Vestibular Research-Equilibrium & Orientation* (2018).
- [41] J. Louza, E. Krause and R. Gurkov, Audiologic evaluation of Meniere's disease patients one day and one week after intratympanic application of gadolinium contrast agent: Our experience in sixty-five patients, *Clinical Otolaryngology* **38** (2013), 262–266.
- [42] J. Louza, E. Krause and R. Gurkov, Hearing function after intratympanic application of gadolinium-based contrast agent: A long-term evaluation, *Laryngoscope* **125** (2015), 2366–2370.
- [43] J.P. Louza, W. Flatz, E. Krause and R. Gurkov, Short-term audiologic effect of intratympanic gadolinium contrast agent application in patients with Meniere's disease, *Am J Otolaryngol* **33** (2012), 533–537.
- [44] S. Naganawa, H. Kawai, M. Sone and M. Ikeda, Ratio of Vestibular Endolymph in Patients with Isolated Lateral Semicircular Canal Dysplasia, *Magn Reson Med Sci* (2015).
- [45] H. Neuhauser and T. Lempert, Vestibular migraine, *Neurol Clin* **27** (2009), 379–391.
- [46] I. Pyykko, T. Nakashima, T. Yoshida, J. Zou and S. Naganawa, Meniere's disease: A reappraisal supported by a variable latency of symptoms and the MRI visualisation of endolymphatic hydrops, *Bmj Open* **3** (2013).
- [47] F. Simon, J.P. Guichard, R. Kania, J. Franc, P. Herman and C. Hautefort, Saccular measurements in routine MRI can predict hydrops in Meniere's disease, *Eur Arch Otorhinolaryngol* **274** (2017), 4113–4120.
- [48] N.M. Sperling, M.M. Paparella, T.H. Yoon and D. Zelterman, Symptomatic versus asymptomatic endolymphatic hydrops: A histopathologic comparison, *Laryngoscope* **103** (1993), 277–285.
- [49] W. Sun, P. Guo, T. Ren and W. Wang, Magnetic resonance imaging of intratympanic gadolinium helps differentiate vestibular migraine from Meniere disease, *Laryngoscope* (2017).
- [50] M. Tunon Gomez, D.R. Lobo Duro, B. Brea Alvarez and J.R. Garcia-Berrocal, Diagnosis of endolymphatic hydrops by means of 3T magnetic resonance imaging after intratympanic administration of gadolinium, *Radiologia* **59** (2017), 159–165.
- [51] V. Volgger, E. Krause, B. Ertl-Wagner and R. Gurkov, [Hydropic inner ear disease of the vestibular type], *HNO* **64** (2016), 676–679.
- [52] Q. Wu, C. Dai, M. Zhao and Y. Sha, The correlation between symptoms of definite Meniere's disease and endolymphatic hydrops visualized by magnetic resonance imaging, *Laryngoscope* **126** (2016), 974–979.
- [53] T. Yamashita and H.F. Schuknecht, Apical endolymphatic hydrops, *Archives of Otolaryngology* **108** (1982), 463–466.